At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
TAS-102 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study With Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Patients With Microsatellite Stable Refractory Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating TAS-102 and nivolumab for Refractory Metastatic Colorectal Cancer. Completed, enrolled 18 participants across 3 sites.
Detailed Summary
A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Metastatic Colorectal Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartAug 2016
Primary CompletionAug 2017
Study CompletionSep 2017
TodayJul 2026
First PostedAug 9, 2016
Enrollment StartAug 29, 2016
Primary CompletionAug 1, 2017
Study CompletionSep 7, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.9 years ago
Interventions
TAS-102drug
One Arm Only (of TAS 102 plus nivolumab)
nivolumabdrug
One Arm Only (of TAS 102 plus nivolumab)